Bask Health's AI Agent Marketplace Sets Q1 2027 Launch for 500 Telehealth Brands
Bask Health plans an AI-agent marketplace connecting ChatGPT, Claude, and Grok to 500 virtual-care brands. The model shifts platform competition toward agent-mediated access but raises identity, consent, and clinical-safety questions for enterprise buyers.
Bask Health targets AI-native patient acquisition through Model Context Protocol
Bask Health acquired the Telehealth.com domain and plans to launch an agentic telehealth marketplace in Q1 2027, connecting patients and AI agents with more than 500 virtual-care brands through the Model Context Protocol. The marketplace will enable access through ChatGPT, Claude, and Grok, positioning Bask against traditional telehealth infrastructure vendors such as Amwell, Teladoc Health, and Included Health while competing with AI-native patient-access layers.
The company reports processing more than $2 billion in cumulative transactions, up from $1 billion in March 2026. Bask markets an integrated stack including no-code onboarding, provider networks, EHR connectivity, e-prescribing, 50-state pharmacy fulfillment, compounding integrations, automated billing, and HIPAA compliance.
For enterprise buyers evaluating white-label or embedded telehealth platforms, the MCP-based model introduces a new patient-acquisition channel but also material risks around identity verification, consent workflows, clinical escalation, hallucinated care navigation, brand governance, and auditability. The 500-brand target suggests marketplace reach, but Bask has not disclosed enterprise pricing, take rate, clinical-safety benchmarks, or live utilization data. Without those details, the commercial case remains unproven.
Zoom invests in Medaica to extend video into connected diagnostics
Zoom Ventures made a strategic investment in Medaica, whose Telehealth 2.0 platform is designed for remote examination, detection, diagnosis, and real-time monitoring. The investment amount and valuation were not disclosed. Medaica is developing an ecosystem combining medical devices, AI, and diagnostic tools to extend clinical examinations into homes and care facilities.
The move positions Zoom beyond communications infrastructure and into the connected-care territory occupied by Teladoc's remote-monitoring offerings, Amwell's connected-care platform, Microsoft Teams-based healthcare deployments, and device-enabled virtual-care vendors.
Health systems should treat this as a potential future alternative to assembling Zoom or Teams video, third-party examination peripherals, remote-patient-monitoring software, and diagnostic integrations separately. However, Zoom disclosed neither investment size nor validated accuracy, deployment count, reimbursement performance, device certifications, or clinical outcomes. Procurement teams should wait for evidence of FDA-cleared components, integration standards, security architecture, and measurable diagnostic performance before evaluating the platform commercially.
Doximity reaches 190 health systems with clinical AI and telehealth integration
Doximity reported that more than 190 health systems had purchased its clinical AI suite, up from 165 in the prior quarter—an increase of at least 25 customers, or roughly 15% quarter-over-quarter growth. NewYork-Presbyterian deployed Doximity's AI tools across 10 hospitals and hundreds of locations, integrating them into its EHR workflow. The deployment includes Doximity Scribe and Doximity Ask, with Wolters Kluwer's UpToDate clinical content embedded into Doximity Ask.
NewYork-Presbyterian has used Doximity for video and phone visits since 2021, so the expansion links telehealth communications with documentation and clinical decision support rather than treating video as a standalone product. Doximity now competes more directly with Microsoft Nuance DAX Copilot, Abridge, Suki, Amazon One Medical's AI initiatives, and EHR-native tools from Epic and Oracle Health.
The key buying signal is workflow consolidation: a health system can potentially procure telehealth communications, ambient documentation, and clinical information access through a provider-oriented platform. Buyers should demand evidence beyond customer counts—such as note-completion time, clinician adoption, error rates, reimbursement impact, governance controls, and whether integrations are native to their EHR. The 190-system figure demonstrates commercial traction, but it is not a clinical-outcomes benchmark.
What to watch: controlled-substance prescribing and state-by-state compliance
Telehealth operators face a near-term compliance deadline for controlled-substance prescribing. Current federal telemedicine flexibilities run through December 31, 2026, while Medicare telehealth flexibilities extend through December 31, 2027. The distinction matters for platform road maps because prescribing workflows, clinician licensing, payer enrollment, and state-by-state practice requirements cannot be treated as one uniform national capability.
For enterprise buyers, the practical implication is to require configurable prescribing and compliance controls, documented state coverage, HIPAA business-associate agreements, audit trails, and an explicit plan for the post-2026 controlled-substance rules. Vendors that sell "50-state" coverage without specifying which services, clinicians, pharmacies, and prescribing categories are included should be treated cautiously. The shift from basic video visits to agent-mediated access, connected diagnostics, and EHR-integrated workflows increases the surface area for compliance risk—and the cost of getting it wrong.
Technology decisions, clearly explained.
Weekly analysis of the tools, platforms, and strategies that matter to B2B technology buyers. No fluff, no vendor spin.
